Abstract
Vascular endothelial growth factor (VEGF), known as a primary mediator of tumor-induced angiogenesis, is now understood to have a role in tumor-associated immunosuppression. Initially, VEGF was identified to alter the growth and maturation of the immature granulocyte-macrophage progenitors, and more recently it has been noted that it prevents dendritic cell (DC) precursors from developing into mature, antigenpresenting DC. VEGF is associated with recruitment of macrophages to the tumor stroma and VEGF inhibition of myeloid progenitor maturation is associated with the development tumor associated macrophages (TAM) which possess immunosuppressive capacity as well. Therapies intended to inhibit VEGF or VEGF receptors have demonstrated improved anti-tumor immunity and enhanced responses to cancer vaccines.
Current Molecular Medicine
Title: Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression
Volume: 9 Issue: 6
Author(s): Benjamin Johnson, Takuya Osada, Timothy Clay, Herbert Lyerly and Michael Morse
Affiliation:
Abstract: Vascular endothelial growth factor (VEGF), known as a primary mediator of tumor-induced angiogenesis, is now understood to have a role in tumor-associated immunosuppression. Initially, VEGF was identified to alter the growth and maturation of the immature granulocyte-macrophage progenitors, and more recently it has been noted that it prevents dendritic cell (DC) precursors from developing into mature, antigenpresenting DC. VEGF is associated with recruitment of macrophages to the tumor stroma and VEGF inhibition of myeloid progenitor maturation is associated with the development tumor associated macrophages (TAM) which possess immunosuppressive capacity as well. Therapies intended to inhibit VEGF or VEGF receptors have demonstrated improved anti-tumor immunity and enhanced responses to cancer vaccines.
Export Options
About this article
Cite this article as:
Johnson Benjamin, Osada Takuya, Clay Timothy, Lyerly Herbert and Morse Michael, Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression, Current Molecular Medicine 2009; 9 (6) . https://dx.doi.org/10.2174/156652409788970634
DOI https://dx.doi.org/10.2174/156652409788970634 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Selective Inhibitors of Human Neutrophil Proteinase 3
Current Pharmaceutical Design Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design Mouse Models of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Current Pharmaceutical Design A Case of Pantoprazole Anaphylaxis with Cross Reactivity to All Proton Pump Inhibitors: Finding a Safe Alternative
Current Drug Safety Hydroxysafflor Yellow A Attenuates Renal Ischemia- Reperfusion Injury in a Rat Model
Letters in Drug Design & Discovery The Neurovascular Unit: Focus on the Regulation of Arterial Smooth Muscle Cells
Current Neurovascular Research Effect of Leptin on Vascular Nitric Oxide and Endothelial Function
Current Hypertension Reviews Granulocyte Colony-Stimulating Factor Attenuates Blood-Brain Barrier Damage and Improves Cognitive Function in Spontaneously Hypertensive Rats
CNS & Neurological Disorders - Drug Targets The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Lycopene and Cardiovascular Diseases: An Update
Current Medicinal Chemistry Identification of Apoptotic Drugs: Multiparametric Evaluation in Cultured Hepatocytes
Current Medicinal Chemistry Clinical Assessment of Carotid Atherosclerosis Inflammation by Positron Emission Tomography
Current Molecular Medicine Risk Factors, Mechanisms and Treatments of Thromboangiitis Obliterans: An Overview of Recent Research
Current Medicinal Chemistry MMP Inhibitors in Cardiac Diseases: An Update
Recent Patents on Cardiovascular Drug Discovery ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update
Current Pharmaceutical Design Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Antiphospholipid Syndrome as a Neurological Disease
Current Rheumatology Reviews Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design